Arch Virol

1. RIAZ MR, Kamran Ullah SM, Rashid M, Ullah K, et al
   Adaptation of wild-type rabies virus on vaccine producing cell line and its quantification by peroxidase-based immunostaining.
   Arch Virol. 2026;171:254.
   

   >> Share

   
   

   
   BMJ

2. O'DOWD A
   RSV vaccination programme may have halved numbers of baby admissions to ICU.
   BMJ. 2026;394:e100576.
   

   >> Share

   
   
3. TURNER G, Osoro CB, Okello G, Desmond N, et al
   Scaling up malaria vaccines in Africa.
   BMJ. 2026;394:e100502.
   

   >> Share

   
   
4. CORREIA T, McKee M, Gonsalves G
   US policies are making a resurgence of vaccine-preventable diseases inevitable.
   BMJ. 2026;394:e100562.
   

   >> Share

   
   
5. BARANIUK C
   Trump signs order on childhood vaccines while making unproved links between jabs and autism.
   BMJ. 2026;394:e100549.
   

   >> Share

   
   

   
   Clin Infect Dis

6. HOWA AC, Zhu Y, McGonigle T, Nguyen HQ, et al
   Influenza Vaccination and Symptom Burden in Ambulatory Patients with Confirmed Influenza: Evidence from Case-ascertained Household Transmission Studies.
   Clin Infect Dis. 2026 Aug 13:ciag486. doi: 10.1093.
   

   >> Share

   
   

   
   Infect Immun

7. DE PASCALIS R, Espich S, Khan H, Toney M, et al
   Transcriptional analyses of peripheral blood lymphocytes obtained shortly after primary immunization discriminate vaccines against Francisella tularensis.
   Infect Immun. 2026 Aug 14:e0020826. doi: 10.1128/iai.00208.
   

   >> Share

   
   

   
   J Infect

8. KONG M, Gao HX, Song XD, Yang GJ, et al
   Convergent neutralizing antibodies to SARS-CoV-2 variants over 2.5 years after BA.5/BF.7 breakthrough infection.
   J Infect. 2026 Jun 18:106799. doi: 10.1016/j.jinf.2026.106799.
   

   >> Share

   
   

   
   J Infect Dis

9. 
   Correction to: The Long-Term Effect of 2 and 3 Doses of Bivalent HPV Vaccination Against HPV Infections: A Comparison Between 2 Observational Cohort Studies.
   J Infect Dis. 2026 Aug 10:jiag408. doi: 10.1093.
   

   >> Share

   
   
10. LAUNAY O, Piat E, Bonduelle O, Bruhwyler J, et al
    Phase 1, first-in-human, randomized, placebo-controlled, dose-escalating study to evaluate OVX033, a nucleocapsid-based SARS-CoV-2 candidate vaccine.
    J Infect Dis. 2026 Aug 12:jiag409. doi: 10.1093.
    

    >> Share

    
    
11. TSAI CY, Xie M, Cristaldo M, Peluso GR, et al
    BCG vaccination with adjunctive APRIL immunotherapy reduces tuberculosis relapse in mice.
    J Infect Dis. 2026 Aug 12:jiag416. doi: 10.1093.
    

    >> Share

    
    
12. 
    Correction to: Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 RSV Vaccine Administered 24 Months Following a Primary Dose in Adults >/=60 Years of Age.
    J Infect Dis. 2026 Aug 14:jiag422. doi: 10.1093.
    

    >> Share

    
    

    
    J Virol

13. ZHENG M, Pan Z, Jiang Y, Guo Y, et al
    A nanoluciferase-expressing attenuated CHIKV vaccine strain enables rapid and visual drug screening in vitro and in vivo.
    J Virol. 2026 Aug 11:e0046626. doi: 10.1128/jvi.00466.
    

    >> Share

    
    

    
    JAMA

14. RUBIN R
    What to Know About the mRNA Flu Vaccine, Newly Approved by the FDA.
    JAMA. 2026 Aug 14. doi: 10.1001/jama.2026.17069.
    

    >> Share

    
    

    
    N Engl J Med

15. HUANG G, Das R, Wilson E
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults. Reply.
    N Engl J Med. 2026;395:725-726.
    

    >> Share

    
    
16. LOCQUET M, Dogne JM
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;395:724-725.
    

    >> Share

    
    
17. LIU Z, Zhang L, Jiang M
    Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults.
    N Engl J Med. 2026;395:724.
    

    >> Share

    
    

    
    Nat Med

18. NGCOBO M
    Regulatory fragmentation as the hidden barrier to regional vaccine sovereignty.
    Nat Med. 2026 Aug 13. doi: 10.1038/s41591-026-04580.
    

    >> Share

    
    

    
    Pediatr Infect Dis J

19. VAN 'T KRUYS KH, Thielen FW, Borstlap N, Mawie T, et al
    Clinical and Economic Burden of Invasive Pneumococcal Disease in Children in Suriname: A Nationwide Cohort Study From a Middle-income Country in the Absence of a Pneumococcal Immunization Program.
    Pediatr Infect Dis J. 2026;45:812-815.
    

    >> Share

    
    

    
    PLoS One

20. JOHN A, Rasheed R, Idikula MJ
    Perceptions and practices among students, parents, and teachers of the Human Papillomavirus (HPV) Vaccination: A pilot feasibility study from Rural Kerala.
    PLoS One. 2026;21:e0340559.
    

    >> Share

    
    
21. PARK S, Kwon JA, Kim HS, Choi Y, et al
    Socioeconomic differences in influenza vaccination coverage by government financial support status: A population-based study in Korea.
    PLoS One. 2026;21:e0353764.
    

    >> Share

    
    
22. FLOOD T, Hughes CM, Wilson IM, McLaughlin M, et al
    Development of an intervention for middle adolescents (15-17 years old) using the Behaviour Change Wheel (BCW) to empower adolescent decision-making regarding HPV vaccination uptake.
    PLoS One. 2026;21:e0355229.
    

    >> Share

    
    
23. TUT G, Lancaster T, Sylla P, Bone D, et al
    High rates of SARS-CoV-2 reinfection in residents of long term care facilities despite robust spike-specific immunity following serial vaccination.
    PLoS One. 2026;21:e0354079.
    

    >> Share

    
    

    
    Science

24. PRUDENCIO M, Mota MM
    A boost for chemical vaccination against malaria.
    Science. 2026;393:661-662.
    

    >> Share

    
    
25. KUPFERSCHMIDT K
    'Mismatched' Ebola vaccine may soon be rolled out widely.
    Science. 2026;393:649-650.
    

    >> Share

    
    

    
    Vaccine

26. CASUSO A, Rodriguez-Gabilondo A, Leal Y, Gallardo-Escarate C, et al
    Protective and immunostimulatory effects of a vitellogenin functional domain-based vaccine in Atlantic salmon against Caligus rogercresseyi.
    Vaccine. 2026;90:129025.
    

    >> Share

    
    
27. VILLANUEVA-FLORES F, Garcia-Atutxa I
    Risk-aware artificial intelligence for translational vaccine design.
    Vaccine. 2026;90:129047.
    

    >> Share

    
    
28. ZHENG S, Wang L, Xia X, Xin Z, et al
    Advances in research and application of therapeutic antibody strategies for porcine rotavirus prevention and control.
    Vaccine. 2026;88:128777.
    

    >> Share

    
    
29. FAVRE G, Pfund A, Gerbier E, Anselem O, et al
    Acceptability and preferences regarding RSV immunisation during pregnancy: a cross-sectional study in diverse global settings.
    Vaccine. 2026;88:128783.
    

    >> Share

    
    
30. GAZEAU S, Byrne C, Coombs D, Kunzweiler C, et al
    Mathematical modelling highlights the crucial role of early childhood immunization in preventing congenital CMV in countries with high CMV seroprevalence.
    Vaccine. 2026;88:128788.
    

    >> Share

    
    
31. RAZZAGHI H, Garacci E, Kahn KE, Meghani M, et al
    Maternal and infant immunizations for respiratory diseases, United States, may 2025.
    Vaccine. 2026;88:128823.
    

    >> Share

    
    
32. WANG J, Li S, Zhou W, Huang J, et al
    Breakthrough varicella infection: a retrospective cohort study based on large-scale real-world data in Guangxi, China, 2014-2025.
    Vaccine. 2026;88:128838.
    

    >> Share

    
    
33. LUO Z, Gu L, Du Z, Cao Z, et al
    Engineered OMVs of Salmonella displaying PlpE antigen provide effective protection against Pasteurella multocida infection in mice.
    Vaccine. 2026;88:128849.
    

    >> Share

    
    
34. DOWALL SD, Findlay-Wilson S, Graham VA, Yara DA, et al
    Protective titre of the WHO international standard for anti-chikungunya virus antibodies in a mouse model.
    Vaccine. 2026;88:128927.
    

    >> Share

    
    
35. TU T, Tseng CY, Islam MD, Hsu WL, et al
    Adjuvant-free pH-controlled aggregates of E. coli-expressed H1N1-RBD enhance neutralizing antibody responses and confer protection against influenza virus.
    Vaccine. 2026;88:128898.
    

    >> Share

    
    
36. JAHAN Y, Aziz AB
    Measles outbreaks as signals of governance failure: Lessons from Bangladesh's 2026 immunisation collapse.
    Vaccine. 2026;88:128924.
    

    >> Share

    
    
37. BOCCADIFUOCO G, Fantoni G, Verdirosa F, Petri C, et al
    Qualification of a high-throughput luminescence-based Serum Bactericidal Activity assay to assess the functionality of human sera against five Shigella serotypes.
    Vaccine. 2026;88:128965.
    

    >> Share

    
    
38. LI J, Wang Z, Gong Y
    Country-level immunization recovery and DTP1 no-dose proxy burden after COVID-19: a descriptive ecological analysis of WUENIC, 2010-2024.
    Vaccine. 2026;88:128973.
    

    >> Share

    
    
39. YANG J, Lin T, Lin X, Wang Y, et al
    Intranasal immunization with a P1 adhesin C-terminal-flagellin fusion protein elicits robust systemic and mucosal immunity and protects against Mycoplasma pneumoniae infection in a mouse model.
    Vaccine. 2026;88:128996.
    

    >> Share

    
    
40. TUELLS J
    Letters and lymph: Jean de Carro and the transnational circulation of Jennerian vaccination, 1799-1810.
    Vaccine. 2026;90:129050.
    

    >> Share

    
    
41. KASTING ML, Sutton SK, Davish M, Quinn GP, et al
    Clinicians' self-reported HPV vaccination recommendations for sexual and gender minority patients.
    Vaccine. 2026;90:129037.
    

    >> Share

    
    
42. KAZI F, Shapland CY, Spiga F, Villanueva G, et al
    Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant.
    Vaccine. 2026;90:128993.
    

    >> Share

    
    
43. RAFIZADEH A, Wijekoon D, Aung ET, Aguirre I, et al
    Influenza vaccination uptake among people living with HIV in Melbourne, 2015-2025: a repeated cross-sectional study.
    Vaccine. 2026;90:129038.
    

    >> Share

    
    
44. NEPAL Y, Wondra G, Jones DT, Francian A, et al
    Identification of vaccine candidates by immunization with a complex pool of recombinant VLPs.
    Vaccine. 2026;90:129027.
    

    >> Share

    
    
45. LIU X, Cloughesy JN, Yu T, Ferranna M, et al
    Uptake of the RSVpreF vaccine during pregnancy: associations with socioeconomic status, prenatal care utilization, and maternal risk factors.
    Vaccine. 2026;90:129003.
    

    >> Share

    
    
46. WIYSONGE CS, Bwaka AM, Teka Bekele A, Masresha BG, et al
    Life-course vaccination requires life-course performance metrics.
    Vaccine. 2026;90:129041.
    

    >> Share

    
    
47. AHI T, Andersen KM, Mateus JS, Yu T, et al
    2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults.
    Vaccine. 2026;90:129009.
    

    >> Share

    
    
48. ADDARIO A, Chapoton B, Celarier T, Barth N, et al
    'Healthy ageing' messaging in vaccine promotion among older adults: evaluation of vaccine intention in a survey using a social marketing methodology.
    Vaccine. 2026;90:129018.
    

    >> Share

    
    
49. AKEJU O, Feng S, Clarke E, Bashorun AO, et al
    Seroefficacy of a 10-valent pneumococcal conjugate vaccine (Pneumosil(R)) compared with other pneumococcal conjugate vaccines in children.
    Vaccine. 2026;90:129029.
    

    >> Share

    
    
50. KOONIN LM, Velez SD, Bresee JS
    Expanding adult immunization in low- and middle-income countries through pharmacist-provided vaccination.
    Vaccine. 2026;90:129004.
    

    >> Share

    
    
51. KAZENZA B, Masokolo B, Mbunga B, Egbende L, et al
    Why COVID-19 vaccination struggled in the Democratic Republic of Congo: a qualitative study exploring organizational and sociocultural barriers, 2025.
    Vaccine. 2026;90:129033.
    

    >> Share

    
    
52. COOPER LV, Djedanem M, Nasser AA, Moussa K, et al
    Effectiveness of NmCV-5 vaccine against meningococcal meningitis in an outbreak setting in Niger: results from a case-control study.
    Vaccine. 2026;90:128997.
    

    >> Share

    
    
53. HUIBERTS AJ, Eggink D, de Gier B, Karens T, et al
    Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands.
    Vaccine. 2026;90:129030.
    

    >> Share

    
    
54. CHOWDHURY M
    Rotavirus vaccine coverage and urban-rural equity in India: Evidence from the sixth National Family Health Survey (NFHS-6).
    Vaccine. 2026;90:129031.
    

    >> Share

    
    
55. PAULL KK, Newall AT
    Erratum to "The cost of respiratory syncytial virus (RSV) across all ages to the Australian healthcare system" [Vaccine 88 (2026) 128922].
    Vaccine. 2026 Aug 10:129019. doi: 10.1016/j.vaccine.2026.129019.
    

    >> Share

    
    
56. HUTTON DW, Prosser LA, Ortega-Sanchez IR, Leidner AJ, et al
    Evaluating the cost-effectiveness of respiratory syncytial virus vaccination among risk-stratified older adults.
    Vaccine. 2026;90:129023.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share